ConvaTec is a leading developer and marketer of innovative medical technologies. With four key business divisions: Advanced Wound Care, Ostomy Care, Continence and Critical Care (CCC) and Infusion Devices, ConvaTec products support health care professionals from the hospital to the community health setting. The company has operations in over 100 countries serving consumers and health care professionals on six continents.

Nordic Capital Funds VI and VII acquired a majority shareholding in ConvaTec from Bristol Myers Squibb in August 2008. Since then, the company has grown to become one of the leading medical technology companies globally, with a strong focus on structurally growing chronic care markets and sales to patients and healthcare professionals in more than 100 countries. 

During Nordic Capital's ownership, the company has benefited from ongoing operational improvements, organic growth and complementary acquisitions. Key acquisitions include Unomedical, a leading manufacturer of single-use medical devices based in Copenhagen, which was also backed by Nordic Capital; and 180 Medical, through which ConvaTec distributes intermittent urological catheters directly to patients in the United States. Since Nordic Capital's initial investment in 2008, ConvaTec's number of employees has almost trebled and the company now employs circa 9,000 people.

ConvaTec Group Plc was listed on the London Stock Exchange in October 2016. Together, Nordic Capital Funds VI and VII, owns approximately 7.3% of the shares (as per June 2017).

Key Information

Revenues Icon

Revenues 2016*

EUR 1530 million

Employees Icon



Ownership Icon


Nordic Capital Fund VI and Fund VII, controlling shareholding

Investment Icon

Investment date


* Reported